MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 535292 | Name: Beclamide
Featured New

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Beclamide is a drug that possesses anticonvulsant activity. It is no longer used. Beclamide is possibly metabolized to 3-chloropropanoic acid in vivo, which binds to the GHB receptor. It has been used as a sedative and as an anticonvulsant. It was studied in the 1950s for its anticonvulsant properties, as a treatment for generalised tonic-clonic seizures. It was not effective for absence seizures. Interest in the drug resumed in the 1990s for its psychiatric properties as an adjunct in the treatment of schizophrenia. While not classified as a DEA controlled substance in the United States, this product can only be sold STRICTLY to universities and research institutions. This product will not be sold to individuals or shipped to residential addresses.

Chemical Structure

Beclamide
Beclamide
CAS#501-68-8

Theoretical Analysis

MedKoo Cat#: 535292

Name: Beclamide

CAS#: 501-68-8

Chemical Formula: C10H12ClNO

Exact Mass: 197.0607

Molecular Weight: 197.66

Elemental Analysis: C, 60.77; H, 6.12; Cl, 17.93; N, 7.09; O, 8.09

Price and Availability

Size Price Availability Quantity
100mg USD 550.00 2 Weeks
200mg USD 950.00 2 Weeks
500mg USD 1,650.00 2 Weeks
1g USD 2,450.00 2 Weeks
2g USD 4,450.00 2 Weeks
5g USD 6,950.00 2 Weeks
Show More
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
Beclamide; Neuracen; Chloracon; Chlorakon; Posedrine; Beklamid; Nidrane; Nydrane; Nydran
IUPAC/Chemical Name
N-Benzyl-3-chloropropionamide
InChi Key
JPYQFYIEOUVJDU-UHFFFAOYSA-N
InChi Code
InChI=1S/C10H12ClNO/c11-7-6-10(13)12-8-9-4-2-1-3-5-9/h1-5H,6-8H2,(H,12,13)
SMILES Code
O=C(NCC1=CC=CC=C1)CCCl
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Product Data
Product Data
Instruction
View handling instruction
Biological target:
Beclamide is a drug that possesses anticonvulsant activity.
In vitro activity:
TBD
In vivo activity:
The anti-aggressive effects of orally administered beclamide (N-Benzyl-beta-chloropropionamide) were studied in male albino mice which were individually isolated for a 28-day period. Beclamide (50-250 mg kg-1 p.o.) caused an overall dose-dependent increase in the attack onset latency, a reduction in the percentage of animals attacking and the mean number of attacks/animal for this model of aggression. In addition, the highest dose of beclamide (250 mg kg-1 p.o.) did not significantly modify locomotor activity in mice. It was concluded that beclamide induced anti-aggressive effects at non-sedative doses. This anti-aggressive action was thought be at least partially mediated, through a beclamide-induced release of 5-HT from presynaptic sites. Reference: J Pharm Pharmacol. 1988 Dec;40(12):891-3. https://academic.oup.com/jpp/article-abstract/40/12/891/6176493?redirectedFrom=fulltext
Solvent mg/mL mM
Solubility
DMSO 70.0 354.14
Ethanol 40.0 202.37
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 197.66 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
1. Darmani NA, Sewell RD, Nicholls PJ. Effects of beclamide on isolation-induced aggression and locomotor activity in mice. J Pharm Pharmacol. 1988 Dec;40(12):891-3. doi: 10.1111/j.2042-7158.1988.tb06297.x. PMID: 2907587.
In vitro protocol:
TBD
In vivo protocol:
1. Darmani NA, Sewell RD, Nicholls PJ. Effects of beclamide on isolation-induced aggression and locomotor activity in mice. J Pharm Pharmacol. 1988 Dec;40(12):891-3. doi: 10.1111/j.2042-7158.1988.tb06297.x. PMID: 2907587.
1: Ahmadi M, Nicholls PJ, Smith HJ, Spencer PS, Preet-Ryatt MS, Spragg BP. Metabolism of beclamide after a single oral dose in man: quantitative studies. J Pharm Pharmacol. 1995 Oct;47(10):876-8. doi: 10.1111/j.2042-7158.1995.tb05757.x. PMID: 8583359. 2: Raptis C, Garcia-Borreguero D, Weber MM, Dose M, Bremer D, Emrich HM. Anticonvulsants as adjuncts for the neuroleptic treatment of schizophrenic psychoses: a clinical study with beclamide. Acta Psychiatr Scand. 1990 Feb;81(2):162-7. doi: 10.1111/j.1600-0447.1990.tb06472.x. PMID: 2183543. 3: Darmani NA, Sewell RD, Nicholls PJ. Acute effects of beclamide on brain regional monoamine concentrations, their metabolites and radioligand binding studies. J Pharm Pharmacol. 1991 Jun;43(6):425-9. doi: 10.1111/j.2042-7158.1991.tb03502.x. PMID: 1717674. 4: WILSON J, WALTON JN, NEWELL DJ. Beclamide in intractable epilepsy: a controlled trial. Br Med J. 1959 May 16;1(5132):1275-8. doi: 10.1136/bmj.1.5132.1275. PMID: 13651708; PMCID: PMC1993459. 5: Ozer AY, Hincal AA. Studies on the masking of unpleasant taste of beclamide: microencapsulation and tabletting. J Microencapsul. 1990 Jul-Sep;7(3):327-39. doi: 10.3109/02652049009021843. PMID: 2384836. 6: Movsisyan M, Heugebaert TSA, Roman BI, Dams R, Van Campenhout R, Conradi M, Stevens CV. Atom- and Mass-economical Continuous Flow Production of 3-Chloropropionyl Chloride and its Subsequent Amidation. Chemistry. 2018 Aug 9;24(45):11779-11784. doi: 10.1002/chem.201802208. Epub 2018 Jul 13. PMID: 29879290. 7: Darmani NA, Sewell RD, Nicholls PJ. Effects of beclamide on isolation-induced aggression and locomotor activity in mice. J Pharm Pharmacol. 1988 Dec;40(12):891-3. doi: 10.1111/j.2042-7158.1988.tb06297.x. PMID: 2907587. 8: Darmani NA, Sewell RD, Hasan MY, Nicholls PJ. Comparison of the inhibitory action of aminobeclamide and beclamide on socially offensive behaviour. J Pharm Pharmacol. 1990 Jun;42(6):447-9. doi: 10.1111/j.2042-7158.1990.tb06591.x. PMID: 1979631. 9: Leach H, Lewis M, Luscombe DK, Nicholls PJ. Studies of plasma levels and the excretion of beclamide in normal human subjects [proceedings]. Br J Clin Pharmacol. 1975 Aug;2(4):377P-378P. PMID: 1234008. 10: Nicholls PJ, Ross MS, Luscombe DK. Metabolism of beclamide, N-benzyl-3-chloropropionamide, in man. Xenobiotica. 1979 Feb;9(2):129-40. doi: 10.3109/00498257909038713. PMID: 433311. 11: Jones OP, Leach H, Luscombe DK, Nicholls PJ. A simple method for the determination of beclamide in plasma by gas chromatography. Br J Clin Pharmacol. 1975 Aug;2(4):364-5. doi: 10.1111/j.1365-2125.1975.tb02788.x. PMID: 1233999; PMCID: PMC1402593. 12: Sawaya MC, Horton RW, Meldrum BS. Effects of anticonvulsant drugs on the cerebral enzymes metabolizing GABA. Epilepsia. 1975 Nov;16(4):649-55. doi: 10.1111/j.1528-1157.1975.tb04747.x. PMID: 9890792. 13: Rydzynski Z, Kocur J, Czarnecka E. Effets du béclamide sur le comportement des animaux [Effects of beclamide on animal behavior]. Therapie. 1977 May- Jun;32(3):365-74. French. PMID: 563113. 14: Luscombe DK, Nicholls PJ. Proceedings: Potential tolerance to beclamide and related drug interactions. J Pharm Pharmacol. 1975 Dec;27 Suppl?-2:18P. PMID: 2690. 15: Skerritt JH, Johnston GA. Inhibition of amino acid transmitter release from rat brain slices by phenytoin and related anticonvulsants. Clin Exp Pharmacol Physiol. 1983 Sep-Oct;10(5):527-33. doi: 10.1111/j.1440-1681.1983.tb00221.x. PMID: 6139193. 16: Cornelis J, Chaillet F. Détermination simultanée par chromatographie liquide haute performance de huit antiépileptiques et sédatifs dans le plasma. Utilisation d'un système à compression radiale de la colonne [Simultaneous high performance liquid chromatographic determination of 8 anti-epileptics and sedatives in plasma. Use of a radial compression column system]. Ann Biol Clin (Paris). 1984;42(4):295-9. French. PMID: 6497073. 17: KAYE N, JONES IH, WARRIER GK. Nydrane as an anticonvulsant. Br Med J. 1959 Mar 7;1(5122):627-9. doi: 10.1136/bmj.1.5122.627. PMID: 13629072; PMCID: PMC1992701. 18: Darling CM, Pryor P. Anticonvulsant activity of alkyl-substituted N-benzylcyanoacetamides. J Pharm Sci. 1979 Jan;68(1):108-10. doi: 10.1002/jps.2600680137. PMID: 758443. 19: GANIDEL G, MERVEILLE P, QUEVAUVILBER A, THUILLIER J. Traitement de quelques cas d'épilepsie par un nouvel antiépileptique: la-N-benzyl beta chloro propionamide [N-benzyl-3-chloropropionamide, a new anticonvulsant, in therapy of some cases of epilepsy]. Ann Med Psychol (Paris). 1953 Nov;111(2 4):531-6. Undetermined Language. PMID: 13125052. 20: ARTEMENKO GN, KEVERINA NV. [Chloracon--an antiepileptic drug]. Med Prom SSSR. 1961 Dec;12:57. Russian. PMID: 13862637.